Navigation Links
Amgen's Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
Date:7/26/2012

aranteed and actual results may differ materially from those we project.  The Company's results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments (domestic or foreign) involving current and future products, sales growth of recently launched products, competition from other products (domestic or foreign) and difficulties or delays in manufacturing our products.  In addition, sales of our products are affected by reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and health care cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement.  Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products.  Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities.  We, or others, could identify safety, side effects or manufacturing problems with our products after they are on the market.  Our business may be impacted by government investigations, litigation and product liability claims.  Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors.  We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.  In addition, we compete with other companies with respect to some of our mar
'/>"/>
SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Rapid Fire Marketing Funds Development of Second Generation Vapor Inhaler
2. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
3. Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Second Quarter Financial Results And Conference Call
4. The Female Health Company Reports Second Quarter Operating Results
5. Winner Medical Group Inc. to Host Second Quarter 2012 Earning Conference Call on Thursday, May 10, 2012 at 9:00 p.m. EDT
6. Biodel to Report Second Quarter Fiscal Year 2012 Financial Results on May 10, 2012
7. Landauer, Inc. Reports Fiscal 2012 Second Quarter Results
8. Elsevier Launches Second Annual Mosbys Superheroes of Nursing Contest During Nurses Week 2012
9. BD and Heart to Heart International Collaborate on Second Volunteer Service Trip to Help Improve Healthcare in Haiti
10. HIV Vaccine Trials Network Opens Enrollment for Phase 1 Trial of GeoVax Labs Second Generation HIV Vaccine
11. Johnson & Johnson Expects to Incur Special Charge in Second Quarter for Previously Disclosed Legal Matters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 22, 2015  Amgen (NASDAQ: AMGN ... termination of its participation in the co-development ... STO:AZN and NYSE: AZN ).  Brodalumab, ... for patients with moderate-to-severe plaque psoriasis, psoriatic ... based on events of suicidal ideation and ...
(Date:5/22/2015)... , May 22, 2015  BioLife Solutions, Inc. (NASDAQ: ... proprietary clinical grade hypothermic storage and cryopreservation ... for cells and tissues ("BioLife" or the "Company"), announced that ... MicroCap Conference. The Company is scheduled to ... May 27, 2015 at the Grand Hyatt Hotel in ...
(Date:5/22/2015)... May 22, 2015 The North American ... and is estimated to reach $90.7 million by 2019, at ... Browse through the TOC of North America Dental Lasers Market ... help of various tables and figures. http://www.micromarketmonitor.com/market/north-america-dental-lasers-1771208223.html ... on this report.   Dental lasers are ...
Breaking Medicine Technology:Amgen to terminate participation in co-development and commercialization of brodalumab 2Amgen to terminate participation in co-development and commercialization of brodalumab 3Amgen to terminate participation in co-development and commercialization of brodalumab 4Amgen to terminate participation in co-development and commercialization of brodalumab 5BioLife Solutions To Present At The 2015 Marcum MicroCap Conference In New York City 2North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 2North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 3
... new analysis,presented today from METEOR (Measuring Effects on ... (rosuvastatin calcium) 40,mg slowed the progression of carotid ... levels of risk for cardiovascular disease.,The sub- study ... risk,assessment tool as having less than two or ...
... ORLANDO, Fla., Nov. 7 Astellas Pharma US, ... conversion to normal heart rhythm (sinus rhythm, or ... artery bypass,graft (CABG) or valvular surgeries. AF is ... rhythm and a high heart rate. The study,results ...
Cached Medicine Technology:New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 2New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 3New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 4New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 5New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 6Study Shows Vernakalant Hydrochloride is Effective in Conversion to Normal Heart Rhythm in Atrial Fibrillation Patients Following Cardiac Surgery 2Study Shows Vernakalant Hydrochloride is Effective in Conversion to Normal Heart Rhythm in Atrial Fibrillation Patients Following Cardiac Surgery 3
(Date:5/25/2015)... A recent report for Mass Live made ... a direct result of an opiate overdose in the state ... overdose deaths attributed to prescription opiate medications, and heroin. Mass ... geography. This issue doesn’t care about race. This issue doesn’t ... the state of Mass. reels from the effects of the ...
(Date:5/25/2015)... CA (PRWEB) May 25, 2015 Join Fiona's ... a free two-hour instructional clinic. Irish National Player, Fiona ... and give them a taste of her coaching style. Fiona ... and Novato. Camps in Novato are at Lynwood Elmentary School ... , Novato High School - June 6th, 2015 - 1:00-3:00pm. ...
(Date:5/25/2015)... TX (PRWEB) May 25, 2015 Decora Preset ... company ‘Leviton’ is now available on ‘The Hardware City.’ The ... user has to set a time and the related electronic ... When contacted a representative of the company said, “We are ... Hardware City.’ Now customers can buy Countdown Timer Switch in ...
(Date:5/24/2015)... May 24, 2015 For people who ... Chinese Enterokinase Industry, 2009-2019 Market Research Report would be ... an exhaustive study on the present market scenario of ... into the growing Chinese market of this industry. The ... overall status of the manufacturers in this industry. The ...
(Date:5/24/2015)... York (PRWEB) May 24, 2015 ... lawsuits ( http://www.testosteronelawsuithub.com/ ) has scheduled its next ... of the multidistrict litigation. According to court documents ... of Illinois, the Conference will be convened on ... Testosterone Replacement Therapy Product Liability Litigation - MDL ...
Breaking Medicine News(10 mins):Health News:Opioid Deaths Increase by 33 Percent Since 2012 in Mass. 2Health News:US Sports Camps and Nike Soccer Camps Offer Complimentary Instructional Clinic with Fiona's Soccer Camp 2Health News:Leviton's Decora 60 Minute Countdown Timer Available On ‘The Hardware City’ 2Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 2Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 3Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 4Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 3
... Patient Educational Program Urges Americans to ,Fight Against Heart ... ... Many U.S. adults are confused about,what heart failure is, cannot ... is a manageable condition, according,to a new survey conducted by Harris ...
... becomes newest reseller ... wireless microphone, MAYNARD, Mass., Feb. 12 ... enhancing collaboration, today announced,that the Dictaphone Healthcare Solutions ... Wireless Microphone alongside its Dragon(R),NaturallySpeaking(R) Medical speech recognition ...
... Video Blogs on,DeterminedToQuit.com, HARRISBURG, Pa., Feb. 12 ... to quit using tobacco are,now being featured on ... site, http://www.DeterminedToQuit.com ., Angela and Justin ... than a,year and are determined to quit smoking ...
... Organizations Support Wyeth Campaign to Eliminate Compounded ... International,Academy of Compounding Pharmacists (IACP) today called ... and the North American,Menopause Society (NAMS) to ... dispensing advice to patients and practitioners that ...
... Findings suggest some individuals or families may have underlying ... -- People with a personal or family history of ... rare type of dementia that causes them to lose ... report. , The condition, known as primary progressive ...
... PLANO, Texas, Feb. 12 With the recent announcement ... is an ongoing,safety review of Botox Cosmetic (botulinum toxin ... lines between the brows. Botox(R),Cosmetic received FDA approval in ... lines between the brows in people 18 to 65 ...
Cached Medicine News:Health News:New Survey Suggests Confusion, Lack of Awareness About Heart Failure Could Be Preventing Critical Early Detection and Treatment 2Health News:New Survey Suggests Confusion, Lack of Awareness About Heart Failure Could Be Preventing Critical Early Detection and Treatment 3Health News:New Survey Suggests Confusion, Lack of Awareness About Heart Failure Could Be Preventing Critical Early Detection and Treatment 4Health News:New Survey Suggests Confusion, Lack of Awareness About Heart Failure Could Be Preventing Critical Early Detection and Treatment 5Health News:New Survey Suggests Confusion, Lack of Awareness About Heart Failure Could Be Preventing Critical Early Detection and Treatment 6Health News:Revolabs xTag(TM) Wireless Microphone Now Offered as a Total Solution With Dragon(R) NaturallySpeaking(R) Medical Software from Nuance 2Health News:Revolabs xTag(TM) Wireless Microphone Now Offered as a Total Solution With Dragon(R) NaturallySpeaking(R) Medical Software from Nuance 3Health News:American Association of Clinical Endocrinologists and North American Menopause Society Fail to Disclose Financial Ties to Wyeth Pharmaceuticals 2Health News:Learning Disabilities May Presage Later Language Problems 2Health News:Botox Cosmetic Alternatives Are Available: Surgical Procedures Offer Solution for Wrinkles 2
... of German Craftsmanship have ... instrumentation in the world. ... available to you! Only ... Meisterbrief certificate, which requires ...
... Products are constructed of a ... MEROCEL polyvinyl acetal sponge. Each ... beneficial to both surgeon and ... yet firm enough to gently ...
... KeraCel Ophthalmic Products are ... formulation of lint-free MEROCEL polyvinyl ... configured to be beneficial to ... being absorbent, and yet firm ...
... Ophthalmic Products are constructed of ... lint-free MEROCEL polyvinyl acetal sponge. ... be beneficial to both surgeon ... and yet firm enough to ...
Medicine Products: